DSIP (Delta Sleep-Inducing Peptide)

Despite its name, evidence for reliable sleep induction in humans is inconsistent. Small studies show mixed results for insomnia and chronic pain.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Early European studies showed some effects on sleep EEG patterns. Results have been inconsistent across trials. Interest has waned in mainstream research.

• Some EEG data suggesting modulation of sleep architecture
• Possible stress-response modulation in small studies
• Opioid-withdrawal symptom reduction in limited data

Historical protocols: 100–300 mcg IV or intranasal. No standardized dosing exists.

• Headache
• Transient hypotension
• Injection-site reactions

Not approved in any major market. Gray-market products may have quality issues. Blood-brain barrier penetration is uncertain.

The peptide's name oversells the evidence. Sleep-inducing effects are not consistently replicated.

• Sleep30
• Stress20
• Pain20